Clinical trial • Phase II • Endocrinology

somatropin for Growth hormone deficiency

Phase II trial of somatropin for Growth hormone deficiency. 26 participants.

Overview

Trial Therapeutic Area
Endocrinology
Trial Disease
Growth hormone deficiency
Trial Stage
Phase II
Drug Modality
Peptide/protein/enzyme

Key dates

Initial CTIS Submission Date
18-02-2026
First CTIS Authorization Date
25-03-2026

Trial design

Phase II trial across 1 site in Belgium.

Target Sample Size
26
Trial Duration For Participant
91

Eligibility

Recruits 26 Vulnerable population selected (isVulnerablePopulationSelected = true); no further details on consent or assent handling provided in the source..

Vulnerable Population
Vulnerable population selected (isVulnerablePopulationSelected = true); no further details on consent or assent handling provided in the source.

Recruitment

Planned Sample Size
26
Recruitment Window Months
3

Methods

  • Site recruitment contact: Pfizer Clinical Research Unit, Brussels, Belgium; email PfizerVolRecruitment@pfizer.com; phone +3225567003
  • Sponsor public contact for inquiries: Clinical Medical Lead, email ClinicalTrials.gov_Inquiries@pfizer.com

Geography

Total Number Of Sites
1
Total Number Of Participants
26

Belgium

Earliest CTIS Part Ii Submission Date
13-03-2026
Latest Decision Or Authorization Date
25-03-2026
Processing Time Days
12
Number Of Sites
1
Number Of Participants
26

Sites

Site Name
Pfizer Clinical Research Unit
Department Name
Not applicable
Contact Person Name
Isabelle Huyghe

Sponsor

Primary sponsor

Full Name
Pfizer Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
Genotropin® (somatropin)
Active Substance
somatropin
Modality
Peptide/protein/enzyme
Routes Of Administration
Subcutaneous (injector pen)
Route
Subcutaneous

Related trials

Other published trials that may interest you.